Cargando…
3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197528/ https://www.ncbi.nlm.nih.gov/pubmed/22028903 http://dx.doi.org/10.1371/journal.pone.0026550 |
_version_ | 1782214320273227776 |
---|---|
author | Knubel, Carolina P. Martínez, Fernando F. Acosta Rodríguez, Eva V. Altamirano, Andrés Rivarola, Héctor W. Diaz Luján, Cintia Fretes, Ricardo E. Cervi, Laura Motrán, Claudia C. |
author_facet | Knubel, Carolina P. Martínez, Fernando F. Acosta Rodríguez, Eva V. Altamirano, Andrés Rivarola, Héctor W. Diaz Luján, Cintia Fretes, Ricardo E. Cervi, Laura Motrán, Claudia C. |
author_sort | Knubel, Carolina P. |
collection | PubMed |
description | BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the known proapoptotic and immunoregulatory properties of 3-HK and their downstream catabolites, it is possible that the 3-HK treatment is effective during the acute phase of the infection by controlling the parasite replication, but at the same time suppressed the protective T cell response before pathogen clearance worsening the chronic phase of the infection. Therefore, in the present study, we investigated the effect of 3-HK treatment on the development of chronic Chagas’ disease. PRINCIPAL FINDINGS: In the present study, we treated mice infected with T. cruzi with 3-HK at day five post infection during 5 consecutive days and investigated the effect of this treatment on the development of chronic Chagas disease. Cardiac functional (electrocardiogram) and histopathological studies were done at 60 dpi. 3-HK treatment markedly reduced the incidence and the severity of the electrocardiogram alterations and the inflammatory infiltrates and fibrosis in heart and skeletal muscle. 3-HK treatment modulated the immune response at the acute phase of the infection impairing the Th1- and Th2-type specific response and inducing TGF-β-secreting cells promoting the emergence of regulatory T cells and long-term specific IFN-γ secreting cells. 3-HK in vitro induced regulatory phenotype in T cells from T. cruzi acutely infected mice. CONCLUSIONS: Our results show that the early 3-HK treatment was effective in reducing the cardiac lesions as well as altering the pattern of the immune response in experimental Chagas’ disease. Thus, we propose 3-HK as a novel therapeutic treatment able to control both the parasite replication and the inflammatory response. |
format | Online Article Text |
id | pubmed-3197528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31975282011-10-25 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease Knubel, Carolina P. Martínez, Fernando F. Acosta Rodríguez, Eva V. Altamirano, Andrés Rivarola, Héctor W. Diaz Luján, Cintia Fretes, Ricardo E. Cervi, Laura Motrán, Claudia C. PLoS One Research Article BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the known proapoptotic and immunoregulatory properties of 3-HK and their downstream catabolites, it is possible that the 3-HK treatment is effective during the acute phase of the infection by controlling the parasite replication, but at the same time suppressed the protective T cell response before pathogen clearance worsening the chronic phase of the infection. Therefore, in the present study, we investigated the effect of 3-HK treatment on the development of chronic Chagas’ disease. PRINCIPAL FINDINGS: In the present study, we treated mice infected with T. cruzi with 3-HK at day five post infection during 5 consecutive days and investigated the effect of this treatment on the development of chronic Chagas disease. Cardiac functional (electrocardiogram) and histopathological studies were done at 60 dpi. 3-HK treatment markedly reduced the incidence and the severity of the electrocardiogram alterations and the inflammatory infiltrates and fibrosis in heart and skeletal muscle. 3-HK treatment modulated the immune response at the acute phase of the infection impairing the Th1- and Th2-type specific response and inducing TGF-β-secreting cells promoting the emergence of regulatory T cells and long-term specific IFN-γ secreting cells. 3-HK in vitro induced regulatory phenotype in T cells from T. cruzi acutely infected mice. CONCLUSIONS: Our results show that the early 3-HK treatment was effective in reducing the cardiac lesions as well as altering the pattern of the immune response in experimental Chagas’ disease. Thus, we propose 3-HK as a novel therapeutic treatment able to control both the parasite replication and the inflammatory response. Public Library of Science 2011-10-19 /pmc/articles/PMC3197528/ /pubmed/22028903 http://dx.doi.org/10.1371/journal.pone.0026550 Text en Knubel et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Knubel, Carolina P. Martínez, Fernando F. Acosta Rodríguez, Eva V. Altamirano, Andrés Rivarola, Héctor W. Diaz Luján, Cintia Fretes, Ricardo E. Cervi, Laura Motrán, Claudia C. 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title | 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title_full | 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title_fullStr | 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title_full_unstemmed | 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title_short | 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease |
title_sort | 3-hydroxy kynurenine treatment controls t. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic chagas disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197528/ https://www.ncbi.nlm.nih.gov/pubmed/22028903 http://dx.doi.org/10.1371/journal.pone.0026550 |
work_keys_str_mv | AT knubelcarolinap 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT martinezfernandof 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT acostarodriguezevav 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT altamiranoandres 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT rivarolahectorw 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT diazlujancintia 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT fretesricardoe 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT cervilaura 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease AT motranclaudiac 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease |